Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1.

Abstract

BACKGROUND\nCamrelizumab, which was launched in China on May 29, 2019, is a humanized anti-Programmed cell Death-1 (PD-1) antibody. It is used for the treatment of complicated or refractory classic Hodgkin s lymphoma with at least second-line chemotherapy. On March 4, 2020, camrelizumab was approved as second-line drug in China for the treatment of patients with advanced hepatocellular carcinoma. Currently, camrelizumab is undergoing clinical research in multiple tumor fields, including advanced solid tumors such as liver cancer, gastric cancer, esophageal cancer, and lung cancer, and all have shown clinical efficacy.\n\n\nOBJECTIVE\nThis review mainly describes the preclinical studies of camrelizumab and its efficacy and safety in clinical studies in various tumors.\n\n\nMETHODS\nA comprehensive literature search was conducted on the basic research and clinical trials of camrelizumab to determine its pharmacology, toxicology, pharmacokinetic properties and current clinical research status. And we analyzed the difference between Karelizumab and other PD-1 antibodies.\n\n\nRESULTS\nThe results of the pre-clinical studies showed that camrelizumab bond to PD-1 receptor and had stable anti-tumor activity in a dose-dependent manner. Clinical studies have shown that camrelizumab has therapeutic effects on a variety of tumors, and it is expected to become a routine drug in the field of tumor therapy in the future. The incidence of adverse reactions with camrelizumab is low and most of them are mild, reversible and predictable.\n\n\nCONCLUSION\nThis review summarizes the current status of preclinical and clinical studies of camrelizumab. Current research data confirm that camrelizumab alone or in combination with other drugs have shown significant anti-cancer activity and lower incidence of adverse reactions, which may be related to its patent. However, further studies are still needed to verify the application potential of camrelizumab in a variety of tumors.